Keyword: Dave Fredrickson
Saturday, AstraZeneca revealed more of the data that convinced the FDA to green-light Calquence in previously untreated chronic lymphocytic leukemia.
Roche’s Tecentriq is the only I-O drug approved in small cell lung cancer. But it may soon have to make some room for AstraZeneca’s Imfinzi.
With 2019’s ASCO officially in the rearview mirror, the question remains: Was this year’s conference “quieter” than in years past? And if so, why?
With key commercial cog Mark Mallon bound for Ironwood’s CEO spot, AstraZeneca is reorganizing into two new R&D and commercial lineups.